We’re transforming scientific potential into reality by building robust and reliable clinical and commercial supply chains for targeted radiotherapies and leading innovators through the complexities of developing, manufacturing, and delivering these therapies.
How we do it
Driving the market for precision radiopharmaceuticals forward, we collaborate with innovators to develop and manufacture breakthrough treatments—overcoming the challenges of working with radioisotopes to deliver safe, effective, and accessible treatments to redefine cancer care.
Why we do it
Our aim is to elevate cancer treatment to unprecedented levels of precision and efficacy, making groundbreaking, minimally invasive therapies the new norm for patients worldwide.
Our story
While science has progressed, presenting new, innovative therapies for more effective and less invasive cancer treatment via targeted radiotherapies, the radiopharmaceutical industry continues to face significant challenges in getting these therapies to the patients who need them.
Many companies, drawn by the potential to significantly impact the fight against cancer, lack the internal capabilities to address the development and supply chain challenges uniquely tied to radioisotopes.
The vision of bringing a life-saving therapy to market often crumbles under the weight of financial risks and logistical failures, especially when dealing with radioisotopes. It is precisely this gap—between the potential of targeted radiotherapies and the reality of bringing them to those in need—that Nucleus RadioPharma was built to fill.
We work hand-in-hand with companies to tackle these challenges at every stage and unite against common enemies: outdated processes and lagging supply chains. Through our comprehensive approach and trusted expertise, we help innovators build and accelerate robust and reliable pipelines within a nascent industry.
We understand that behind every scientific breakthrough, behind every radioisotope, there are people. Patients waiting for better options, families hoping for good news, and clinicians searching for the next advancement.
Our role is to ensure that these targeted radiotherapies reach them on time and, ultimately, transform how we treat cancer.
Transformative CDMO services built by an industry-leading team
Our team, backed by investors such as the Mayo Clinic, possesses a diverse knowledge base that encompasses the pain points of every stakeholder involved: biotech companies, large pharmaceutical companies, clinicians, and patients.
We use this knowledge to serve as your comprehensive end-to-end CDMO services partner. No matter your goals or challenges, we’ll create a plan tailored to your specific needs to ensure success.
150
collective years experience in manufacturing
250
collective years experience in radiopharmaceutical supply chain